Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
About this item
Full title
Author / Creator
LEADER Trial Investigators , LEADER Steering Committee , Marso, Steven P , Daniels, Gilbert H , Brown-Frandsen, Kirstine , Kristensen, Peter , Mann, Johannes F.E , Nauck, Michael A , Nissen, Steven E , Pocock, Stuart , Poulter, Neil R , Ravn, Lasse S , Steinberg, William M , Stockner, Mette , Zinman, Bernard , Bergenstal, Richard M and Buse, John B
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Patients with type 2 diabetes and high cardiovascular risk were assigned to receive either the glucagon-like peptide 1 analogue liraglutide or placebo. The rate of first occurrence of cardiovascular death, nonfatal MI, or nonfatal stroke was lower with liraglutide.
Type 2 diabetes is a complex metabolic disorder that is characterized by hypergly...
Alternative Titles
Full title
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Authors, Artists and Contributors
Author / Creator
LEADER Steering Committee
Marso, Steven P
Daniels, Gilbert H
Brown-Frandsen, Kirstine
Kristensen, Peter
Mann, Johannes F.E
Nauck, Michael A
Nissen, Steven E
Pocock, Stuart
Poulter, Neil R
Ravn, Lasse S
Steinberg, William M
Stockner, Mette
Zinman, Bernard
Bergenstal, Richard M
Buse, John B
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4985288
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4985288
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1603827
